MA40867A - Méthodes pour le traitement d'infections virales à filoviridae - Google Patents
Méthodes pour le traitement d'infections virales à filoviridaeInfo
- Publication number
- MA40867A MA40867A MA040867A MA40867A MA40867A MA 40867 A MA40867 A MA 40867A MA 040867 A MA040867 A MA 040867A MA 40867 A MA40867 A MA 40867A MA 40867 A MA40867 A MA 40867A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- methods
- viral infections
- filoviridae viral
- filoviridae
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2429—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of arylalkanols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/02—Phosphorylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/18—Acyclic radicals, substituted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/06—Heterocyclic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462072331P | 2014-10-29 | 2014-10-29 | |
US201562105619P | 2015-01-20 | 2015-01-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA40867A true MA40867A (fr) | 2017-09-06 |
Family
ID=54557474
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA040872A MA40872A (fr) | 2014-10-29 | 2015-10-29 | Méthodes pour la préparation de ribosides |
MA040867A MA40867A (fr) | 2014-10-29 | 2015-10-29 | Méthodes pour le traitement d'infections virales à filoviridae |
MA052506A MA52506A (fr) | 2014-10-29 | 2015-10-29 | Procédés de traitement d'infections par des virus nipah |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA040872A MA40872A (fr) | 2014-10-29 | 2015-10-29 | Méthodes pour la préparation de ribosides |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA052506A MA52506A (fr) | 2014-10-29 | 2015-10-29 | Procédés de traitement d'infections par des virus nipah |
Country Status (45)
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2480559T1 (sl) | 2009-09-21 | 2013-10-30 | Gilead Sciences, Inc. | Postopki in intermediati za pripravo 1'-ciano-karbanukleozidnih analogov |
PT2595980E (pt) | 2010-07-22 | 2014-11-27 | Gilead Sciences Inc | Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae |
TWI698444B (zh) | 2014-10-29 | 2020-07-11 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
CA2998189C (fr) | 2015-09-16 | 2021-08-03 | Gilead Sciences, Inc. | Procedes pour le traitement d'infections virales a arenaviridae et coronaviridae |
US11617753B2 (en) | 2016-11-10 | 2023-04-04 | Oyagen, Inc. | Methods of treating and inhibiting Ebola virus infection |
MA46839A (fr) * | 2016-11-18 | 2021-03-24 | Neurovive Pharmaceutical Ab | Promédicaments hépatiques d'ionophores de protons mitochondriaux |
CN110869028B (zh) | 2017-03-14 | 2023-01-20 | 吉利德科学公司 | 治疗猫冠状病毒感染的方法 |
JP6923112B2 (ja) * | 2017-03-31 | 2021-08-18 | 国立大学法人北海道大学 | フィロウイルスの細胞侵入阻害活性を有するビアリールスルフォンアミド誘導体 |
CN115403626A (zh) | 2017-05-01 | 2022-11-29 | 吉利德科学公司 | 新结晶形式 |
US10675296B2 (en) * | 2017-07-11 | 2020-06-09 | Gilead Sciences, Inc. | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
KR20200098483A (ko) | 2017-09-18 | 2020-08-20 | 얀센 바이오파마, 인크. | 치환된 뉴클레오시드, 뉴클레오티드 및 이들의 유사체 |
CN109535200A (zh) * | 2017-09-21 | 2019-03-29 | 杭州和正医药有限公司 | 一种核苷类似物的磷酰胺酯前药、药物组合物及其应用 |
CN109748944B (zh) * | 2017-11-03 | 2021-12-10 | 中国科学院上海药物研究所 | 5’-脱氧-5’-异丙基取代氨基核苷类化合物、其制备方法和用途 |
CN109748943A (zh) * | 2017-11-03 | 2019-05-14 | 中国科学院上海药物研究所 | 2’-c-甲基取代核苷类化合物及其制备与用途 |
CN110330540A (zh) * | 2019-08-08 | 2019-10-15 | 木天(济南)生物科技有限公司 | 核苷盐及其制备方法 |
CN110613726B (zh) * | 2019-09-25 | 2020-10-16 | 广州六顺生物科技股份有限公司 | 核苷化合物的应用 |
WO2021095091A1 (fr) * | 2019-11-11 | 2021-05-20 | 藤本化学製品株式会社 | Dérivé aminoaryle, produit intermédiaire, et procédés de fabrication de ceux-ci |
CN110776512A (zh) * | 2019-11-28 | 2020-02-11 | 成都傲飞生物化学品有限责任公司 | 一种核苷类似物的制备方法 |
WO2021154687A1 (fr) | 2020-01-27 | 2021-08-05 | Gilead Sciences, Inc. | Procédés de traitement d'infections par sras cov-2 |
WO2021158248A1 (fr) | 2020-02-04 | 2021-08-12 | Oyagen, Inc. | Méthodes de traitement d'infections à coronavirus |
CN113214263B (zh) * | 2020-02-06 | 2022-09-30 | 北京桦冠医药科技有限公司 | 瑞德西韦关键中间体的一种合成方法 |
US20210244705A1 (en) * | 2020-02-07 | 2021-08-12 | Centre For Digestive Diseases | Therapeutic compositions, products of manufacture and methods for ameliorating or preventing coronavirus infection |
CN111205327B (zh) * | 2020-02-17 | 2022-05-31 | 南京法恩化学有限公司 | 一种瑞德西韦的制备方法 |
TWI775313B (zh) * | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
TWI791193B (zh) * | 2020-02-18 | 2023-02-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
TW202322824A (zh) | 2020-02-18 | 2023-06-16 | 美商基利科學股份有限公司 | 抗病毒化合物 |
CN113292565B (zh) * | 2020-02-24 | 2023-01-31 | 浙江森科建设有限公司 | 核苷类化合物及其制备方法和应用 |
CN111171078B (zh) * | 2020-02-27 | 2022-04-22 | 江苏阿尔法药业股份有限公司 | 一种瑞德西韦的合成方法 |
CN111205294B (zh) * | 2020-02-27 | 2021-10-01 | 江苏阿尔法药业股份有限公司 | 一种瑞德西韦中间体的制备方法 |
CN111187269A (zh) * | 2020-02-27 | 2020-05-22 | 江苏阿尔法药业有限公司 | 一种瑞德西韦中间体的合成方法 |
CN111233930B (zh) * | 2020-03-04 | 2022-05-13 | 江苏阿尔法药业股份有限公司 | 一种瑞德西韦的制备方法 |
CN113354699B (zh) * | 2020-03-04 | 2023-07-18 | 中国科学院上海药物研究所 | 瑞德西韦的中间体及其制备方法 |
CN111269248A (zh) * | 2020-03-05 | 2020-06-12 | 江苏福瑞康泰药业有限公司 | 一种核苷氨基磷酸酯类药物母液回收的新方法 |
CN111269263A (zh) * | 2020-03-09 | 2020-06-12 | 上海龙翔生物医药开发有限公司 | 一种瑞德西韦侧链中间体及其制备方法 |
CN113387954B (zh) * | 2020-03-11 | 2024-03-19 | 上海特化医药科技有限公司 | 一种瑞德西韦中间体的制备方法 |
CN111233870A (zh) * | 2020-03-11 | 2020-06-05 | 中国科学技术大学 | 用于快速制备瑞德西韦药物中间体的方法 |
CN111233869B (zh) * | 2020-03-12 | 2022-09-16 | 杭州新博思生物医药有限公司 | 用于制备瑞德西韦关键中间体的新化合物及其制备方法 |
CN115298181A (zh) * | 2020-03-12 | 2022-11-04 | 吉利德科学公司 | 制备1’-氰基核苷的方法 |
JP2023518814A (ja) | 2020-03-23 | 2023-05-08 | ジェネンテック, インコーポレイテッド | Covid-19肺炎における、il-6アンタゴニストに対する応答を予測するためのバイオマーカー |
JP2023518812A (ja) | 2020-03-23 | 2023-05-08 | ジェネンテック, インコーポレイテッド | Covid19肺炎を治療するための、トシリズマブとレムデシビルとの組み合わせ |
CN111233931B (zh) * | 2020-03-26 | 2022-03-22 | 宿迁盛基医药科技有限公司 | 一种瑞德西韦的合成方法 |
CN111398464B (zh) * | 2020-04-02 | 2022-03-08 | 广州隽沐生物科技股份有限公司 | 2-乙基丁基((全氟苯氧基)(苯氧基)磷酰基)-l-丙氨酸酯的检测方法 |
CN111423443A (zh) * | 2020-04-03 | 2020-07-17 | 广州科锐特生物科技有限公司 | 一种4-氨基-7-碘吡咯并[2,1-f][1,2,4]三嗪的制备方法 |
EP4132651A1 (fr) | 2020-04-06 | 2023-02-15 | Gilead Sciences, Inc. | Formulations d'inhalation d'analogues de carbanucléosides à substitution 1'-cyano |
WO2021207386A1 (fr) * | 2020-04-07 | 2021-10-14 | Biocryst Pharmaceuticals, Inc. | Procédés, compositions, et régimes de dosage dans le traitement des infections par le sars-cov-2 |
WO2021208910A1 (fr) * | 2020-04-13 | 2021-10-21 | 山东华铂凯盛生物科技有限公司 | Préparation de polymère pour le traitement d'infections virales, procédé de préparation et utilisation correspondants |
CN111393494A (zh) * | 2020-04-17 | 2020-07-10 | 广东帕派恩生物科技有限公司 | 基于核苷酸结构的化合物、制备方法、用途 |
CN112778310A (zh) * | 2020-04-20 | 2021-05-11 | 中国科学院上海药物研究所 | 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用 |
CN111471070B (zh) * | 2020-04-26 | 2022-05-13 | 江苏阿尔法药业股份有限公司 | 瑞德西韦的合成方法 |
CN111454270A (zh) * | 2020-04-27 | 2020-07-28 | 南通伟顺生物科技有限公司 | 一种含六元环的核苷类化合物及其制备方法 |
CN111440176B (zh) * | 2020-04-28 | 2022-04-26 | 江苏大学 | 金属配合物促进的瑞德西韦中间体的合成方法 |
US10988503B1 (en) * | 2020-05-06 | 2021-04-27 | Nantong Weishun Biotechnology Co., Ltd | Six-membered ring-containing nucleoside compound and preparation method thereof |
CN113637041B (zh) * | 2020-05-11 | 2024-02-27 | 上海科胜药物研发有限公司 | 一种核糖核苷的制备方法 |
RU2740660C1 (ru) * | 2020-05-20 | 2021-01-19 | Общество С Ограниченной Ответственностью "Промомед Рус" | Противовирусная композиция |
US20230277524A1 (en) | 2020-05-22 | 2023-09-07 | Trailhead Biosystems Inc. | Combination therapy for treatment of viral infections |
CN111961057A (zh) * | 2020-05-26 | 2020-11-20 | 李小冬 | 一种α构型核苷及其在治疗猫冠状病毒感染的应用 |
IN202011022634A (fr) | 2020-05-29 | 2020-10-09 | Jubilant Generics Limited | |
WO2021240543A1 (fr) | 2020-05-29 | 2021-12-02 | Jubilant Generics Limited | Compositions pharmaceutiques transmuqueuses de médicaments antiviraux |
CA3179226A1 (fr) | 2020-05-29 | 2021-12-02 | Tomas Cihlar | Methodes de traitement par remdesivir |
CN113754692B (zh) * | 2020-06-03 | 2022-06-10 | 上海交通大学 | 瑞德西韦中间体(s,s)-氨基磷酸酯的不对称催化合成方法 |
CN113754693B (zh) * | 2020-06-03 | 2022-09-09 | 上海交通大学 | 一种磷手性核苷衍生物的不对称催化合成方法及催化剂 |
CN113754694B (zh) * | 2020-06-03 | 2022-10-25 | 上海交通大学 | 一种不对称催化无保护基核苷合成瑞德西韦的方法 |
WO2021257569A1 (fr) * | 2020-06-15 | 2021-12-23 | Metro International Biotech, Llc | Composés antiviraux et leurs procédés d'utilisation |
US20230241225A1 (en) | 2020-06-15 | 2023-08-03 | Metro International Biotech, Llc | Anti-viral compounds and methods of use |
CN111620903A (zh) * | 2020-06-17 | 2020-09-04 | 安徽贝克联合制药有限公司 | C-核苷类似物以及用于合成瑞德西韦合成的含腈c-核苷类化合物的制备方法及其应用 |
US20210393663A1 (en) * | 2020-06-23 | 2021-12-23 | Cai Gu Huang | Pharmaceutical formulation containing active metabolites of remdesivir or its analog for inhalation |
CN115996928A (zh) | 2020-06-24 | 2023-04-21 | 吉利德科学公司 | 1’-氰基核苷类似物及其用途 |
CN111732618A (zh) * | 2020-07-03 | 2020-10-02 | 镇江巨杰新材料技术研发中心(有限合伙) | 瑞德西韦关键片段的合成方法 |
CN111961079A (zh) * | 2020-07-17 | 2020-11-20 | 南京正济医药研究有限公司 | 一种瑞德西韦有关物质及其制备方法和应用 |
MX2023001002A (es) * | 2020-07-24 | 2023-03-01 | Univ California | Farmacos antivirales, composiciones farmaceuticas, y metodos. |
EP4192839A1 (fr) | 2020-08-06 | 2023-06-14 | Richter Gedeon Nyrt. | Intermédiaires de remdésivir |
CN113004330A (zh) * | 2020-08-22 | 2021-06-22 | 齐鲁制药有限公司 | 一种高纯度瑞德西韦的制备方法 |
PE20231983A1 (es) | 2020-08-27 | 2023-12-12 | Gilead Sciences Inc | Compuestos y metodos para el tratamiento de infecciones virales |
CN114105989A (zh) * | 2020-08-31 | 2022-03-01 | 中国科学院大连化学物理研究所 | 一种碘代吡咯并三嗪胺类化合物的制备方法和应用 |
CN116685351A (zh) | 2020-09-17 | 2023-09-01 | 基因泰克公司 | Empacta的结果:一项用于评估托珠单抗在患有covid-19肺炎的住院患者中的功效和安全性的随机、双盲、安慰剂对照、多中心研究 |
CN112321642A (zh) * | 2020-09-28 | 2021-02-05 | 南京正济医药研究有限公司 | 一种瑞德西韦有关物质及其制备方法和用途 |
WO2022074630A1 (fr) * | 2020-10-09 | 2022-04-14 | Auxilla Pharmaceuticals And Research Llp | Suspension orale liquide de favipiravir |
CN112194661B (zh) * | 2020-10-22 | 2021-06-08 | 威海同丰海洋生物科技有限公司 | 一种4-氨基-7-碘吡咯并[2,l-f][l,2,4]三嗪的制备方法 |
RU2756921C1 (ru) * | 2020-11-20 | 2021-10-07 | Общество С Ограниченной Ответственностью "Технология Лекарств" | Способ получения ремдесивира и фосфорамидаты |
CA3200885A1 (fr) | 2020-11-23 | 2022-05-27 | Genentech, Inc. | Methodes de modulation des interactions de surfaces de cellules hotes avec le sars-cov-2 |
CN112358513A (zh) * | 2020-12-02 | 2021-02-12 | 上海朴颐化学科技有限公司 | 一种利用连续流反应器制备瑞德西韦中间体的方法 |
CN114621229A (zh) * | 2020-12-11 | 2022-06-14 | 嘉兴金派特生物科技有限公司 | 治疗或预防猫传染性腹膜炎的化合物或组合物 |
CN114685558A (zh) * | 2020-12-28 | 2022-07-01 | 尚科生物医药(上海)有限公司 | 一种瑞德西韦中间体的制备方法 |
CN117777141A (zh) * | 2020-12-30 | 2024-03-29 | 南方科技大学 | 一种抗病毒感染的核苷类化合物及其用途 |
CN113754665B (zh) * | 2020-12-30 | 2022-08-19 | 南方科技大学 | 一种核苷类化合物的制备方法 |
WO2022166581A1 (fr) * | 2021-02-07 | 2022-08-11 | 石家庄迪斯凯威医药科技有限公司 | Dérivé nucléotidique, composite pharmaceutique de celui-ci et son utilisation |
WO2022174779A1 (fr) * | 2021-02-19 | 2022-08-25 | 南京赛弗斯医药科技有限公司 | Dérivé nucléotidique ayant une activité antitumorale, composition pharmaceutique et utilisation associée |
CN112979736B (zh) * | 2021-03-04 | 2022-03-25 | 南京欧信医药技术有限公司 | 一种瑞德西韦的制备方法 |
AU2022258969A1 (en) | 2021-04-16 | 2023-11-02 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
CN117120444A (zh) | 2021-04-16 | 2023-11-24 | 吉利德科学公司 | 使用酰胺制备卡巴核苷的方法 |
US20230000873A1 (en) | 2021-05-26 | 2023-01-05 | Gilead Sciences, Inc. | Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs |
CN113683640A (zh) * | 2021-08-10 | 2021-11-23 | 浙江华海药业股份有限公司 | 一种丁基瑞德西韦的制备方法 |
CA3229752A1 (fr) | 2021-08-20 | 2023-02-23 | Shionogi & Co., Ltd. | Derives nucleosidiques et leurs promedicaments ayant une action inhibitrice de la croissance virale |
CN113999237B (zh) * | 2021-10-29 | 2023-08-08 | 润佳(苏州)医药科技有限公司 | 一种核苷类前药及其用途 |
KR20230063790A (ko) | 2021-11-02 | 2023-05-09 | 충남대학교산학협력단 | 렘데시비르를 함유하는 나노지질담체, 이의 제조방법 및 이를 포함하는 약학적 조성물 |
CN114409655A (zh) * | 2022-01-26 | 2022-04-29 | 郑州大学 | 3′,4′-不饱和核糖c-核苷类似物及其制备方法 |
WO2023167944A1 (fr) | 2022-03-02 | 2023-09-07 | Gilead Sciences, Inc. | Composés et méthodes pour traiter des infections virales |
CN115028672A (zh) * | 2022-06-14 | 2022-09-09 | 南京正济医药研究有限公司 | 瑞德西韦中间体晶体及其制备方法 |
US11655255B2 (en) | 2022-10-17 | 2023-05-23 | Sph No.1 Biochemical & Pharmaceutical Co., Ltd. | Method for catalytic asymmetric synthesis of phosphorus-stereogenic (P-stereogenic) nucleoside derivative and catalyst used therein |
CN115737675B (zh) * | 2022-11-28 | 2024-03-08 | 安徽农业大学 | 氧化型硒代硫酸钠的制备及其在治疗冠状病毒感染中的应用 |
CN116284135A (zh) * | 2023-05-04 | 2023-06-23 | 南京颐媛生物医学研究院有限公司 | 抗冠状病毒核苷类化合物的制备方法及其应用 |
CN116332996A (zh) * | 2023-05-04 | 2023-06-27 | 南京颐媛生物医学研究院有限公司 | 抗冠状病毒化合物及其制备方法和应用 |
Family Cites Families (154)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
CA2083386C (fr) | 1990-06-13 | 1999-02-16 | Arnold Glazier | Bioprecurseur phosphore |
EP0481214B1 (fr) | 1990-09-14 | 1998-06-24 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Pro-médicaments dérivés de phosphonates |
JPH1017629A (ja) | 1996-07-04 | 1998-01-20 | Kayaku Akzo Kk | ハードコート用樹脂組成物及びその硬化方法 |
US6887707B2 (en) | 1996-10-28 | 2005-05-03 | University Of Washington | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA |
KR20010041533A (ko) | 1998-03-03 | 2001-05-25 | 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 | (2e)-5-아미노-5-메틸헥스-2-엔오산n-메틸-n-((1r)-1-(n-메틸-n-((1r)-1-(메틸카르바모일)-2-페닐에틸)카르바모일)-2-(2-나프틸)에틸)아미드의신규한 염 형태 |
US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
US6475985B1 (en) | 1998-03-27 | 2002-11-05 | Regents Of The University Of Minnesota | Nucleosides with antiviral and anticancer activity |
EP1121361B1 (fr) | 1998-10-16 | 2007-08-29 | Merck Sharp & Dohme Limited | Derives pyrazolo-triazine utilises en tant que ligands des recepteurs gaba |
DE19912636A1 (de) | 1999-03-20 | 2000-09-21 | Aventis Cropscience Gmbh | Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel |
ATE332909T1 (de) * | 1999-03-24 | 2006-08-15 | Exiqon As | Verbesserte synthese für 2.2.1.öbicyclo- nukleoside |
MXPA01012444A (es) * | 1999-06-03 | 2002-07-30 | Abbott Lab | Sintesis de oligonucleotido con acidos de lewis como activadores. |
AUPQ105499A0 (en) | 1999-06-18 | 1999-07-08 | Biota Scientific Management Pty Ltd | Antiviral agents |
US6656915B1 (en) | 1999-09-15 | 2003-12-02 | Biocryst Pharmaceuticals, Inc. | Inhibiting T-cell proliferation |
US6566365B1 (en) | 1999-11-04 | 2003-05-20 | Biochem Pharma Inc. | Method for the treatment of Flaviviridea viral infection using nucleoside analogues |
EA200200778A1 (ru) | 2000-02-18 | 2003-06-26 | Шайре Байокем Инк. | СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ИНФЕКЦИИ ГЕПАТИТА С В ОРГАНИЗМЕ ХОЗЯИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ПРОТИВ ФЛАВИВИРУСА, СОЕДИНЕНИЕ ФОРМУЛЫ Ib - АКТИВНЫЙ АГЕНТ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ИНФЕКЦИИ ГЕПАТИТА С ИЛИ ФЛАВИВИРУСА (ВАРИАНТЫ) |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
EP1294735A2 (fr) | 2000-05-26 | 2003-03-26 | Novirio Pharmaceuticals Limited | Procedes et compositions de traitement des flavivirus et des pestivirus |
CZ304734B6 (cs) * | 2000-07-21 | 2014-09-10 | Gilead Sciences, Inc. | Způsob přípravy 9-[2-(fosfonomethoxy)propyl]adeninu a 9-[2-(fosfonomethoxy)ethyl]adeninu |
US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
KR101201552B1 (ko) | 2000-10-18 | 2012-11-15 | 파마셋 인코포레이티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드 |
AUPR213700A0 (en) | 2000-12-18 | 2001-01-25 | Biota Scientific Management Pty Ltd | Antiviral agents |
RS50236B (sr) | 2001-01-22 | 2009-07-15 | Merck & Co.Inc., | Nukleozidni derivati kao inhibitori rnk-zavisne rnk virusne polimeraze |
DE10145223A1 (de) | 2001-09-13 | 2003-04-03 | Basf Ag | Verfahren zur Herstellung von meso-Zeaxanthin |
US20040006002A1 (en) | 2001-09-28 | 2004-01-08 | Jean-Pierre Sommadossi | Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside |
AT410792B (de) | 2001-12-28 | 2003-07-25 | Dsm Fine Chem Austria Gmbh | Verfahren zur herstellung von geschützten, enantiomeren-angereicherten cyanhydrinen durch in-situ-derivatisierung |
AU2003213628A1 (en) | 2002-02-28 | 2003-09-16 | Biota, Inc. | Nucleoside 5'-monophosphate mimics and their prodrugs |
AU2003217863B9 (en) | 2002-02-28 | 2009-10-29 | Biota Scientific Management Pty Ltd | Nucleotide mimics and their prodrugs |
US20040138170A1 (en) | 2002-03-06 | 2004-07-15 | Montgomery John A. | Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases |
GB0210127D0 (en) | 2002-05-02 | 2002-06-12 | Merck Sharp & Dohme | Therapeutic agents |
GB0210124D0 (en) | 2002-05-02 | 2002-06-12 | Merck Sharp & Dohme | Therapeutic agents |
MXPA04010983A (es) | 2002-05-06 | 2005-02-14 | Genelabs Tech Inc | Derivados de nucleosidos para tratar infecciones por el virus de la hepatitis c. |
AU2003233667A1 (en) | 2002-05-23 | 2003-12-12 | Biocryst Pharmaceuticals, Inc. | Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof |
CN1849142A (zh) | 2002-11-15 | 2006-10-18 | 埃迪尼克斯(开曼)有限公司 | 2′-支链核苷和黄病毒突变 |
NZ542342A (en) | 2003-04-25 | 2009-05-31 | Gilead Sciences Inc | Antiviral phosphonate analogs |
WO2004112687A2 (fr) | 2003-06-26 | 2004-12-29 | Biotron Limited | Compositions et methodes antivirales |
GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
DK1658302T3 (da) | 2003-07-25 | 2010-11-22 | Idenix Pharmaceuticals Inc | Purinnukleosidanaloge til behandling af sygdomme forårsaget af Flavirividae, herunder hepatitis C |
BRPI0414019A (pt) | 2003-08-27 | 2006-10-24 | Biota Inc | nucleosìdios ou nucleotìdio tricìclicos como agentes terapêuticos |
JP2005187428A (ja) * | 2003-12-26 | 2005-07-14 | Univ Of Tokyo | 抗mgl抗体によるフィロウイルス治療薬 |
JP2005185235A (ja) * | 2003-12-26 | 2005-07-14 | Univ Of Tokyo | ウイルス感染に対する感受性診断のための方法およびキット。 |
EA011158B1 (ru) | 2004-03-16 | 2009-02-27 | Бёрингер Ингельхайм Интернациональ Гмбх | Замещённые глюкопиранозилом бензольные производные, содержащие эти соединения лекарственные средства, их применение и способ их получения |
EP1758453B1 (fr) | 2004-06-15 | 2014-07-16 | Merck Sharp & Dohme Corp. | Analogues nucleosidiques de c-purine, servant d'inhibiteurs d'arn-polymerase virale arn-dependante |
WO2006002231A1 (fr) | 2004-06-22 | 2006-01-05 | Biocryst Pharmaceuticals, Inc. | Azanucleosides, leur preparation et leur utilisation comme inhibiteur des arn polymerases virales |
AU2005285045B2 (en) | 2004-09-14 | 2011-10-13 | Gilead Pharmasset Llc | Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives |
CN101043893A (zh) | 2004-10-21 | 2007-09-26 | 默克公司 | 治疗RNA-依赖性RNA病毒感染的氟化吡咯并[2,3-d]嘧啶核苷 |
CA2584367A1 (fr) | 2004-10-21 | 2006-06-22 | Merck & Co., Inc. | Nucleosides de pyrrolo[2,3-d]pyrimidine fluores destines au traitement d'infections ribovirales dependantes de l'arn |
JP5089395B2 (ja) | 2004-10-29 | 2012-12-05 | バイオクライスト ファーマシューティカルズ, インコーポレイテッド | 治療用フロピリミジンおよびチエノピリミジン |
US7687469B2 (en) | 2004-12-16 | 2010-03-30 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
WO2006094347A1 (fr) | 2005-03-08 | 2006-09-14 | Biota Scientific Management Pty Ltd. | Nucleosides bicycliques et nucleotides servant d’agents therapeutiques |
EP2537520A1 (fr) | 2005-03-29 | 2012-12-26 | Biocryst Pharmaceuticals, Inc. | Thérapies hépatiques C |
WO2006116557A1 (fr) | 2005-04-25 | 2006-11-02 | Genelabs Technologies, Inc. | Composes nucleosides pour le traitement d’infections virales |
WO2006121820A1 (fr) | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Promedicaments de phosphoramidate pour traitement d'infections virales |
WO2007027248A2 (fr) | 2005-05-16 | 2007-03-08 | Valeant Research & Development | Analogues de nucleoside cyclique 3', 5' pour le traitement du virus de l'hepatite c (vhc) |
DK2826770T3 (en) | 2005-06-24 | 2019-01-07 | Biotron Ltd | Acylguanidine compounds with antiviral activity |
US8067391B2 (en) | 2005-10-03 | 2011-11-29 | University Health Network | ODCase inhibitors for the treatment of malaria |
WO2007056170A2 (fr) | 2005-11-02 | 2007-05-18 | Bayer Healthcare Ag | Derives pyrrolo-[2,1-f]-[1,2,4]-triazin-4-ylamines inhibiteurs de la igf-1r kinase pour le traitement des cancers et autres maladies hyperproliferatives |
CN101321522B (zh) | 2005-12-01 | 2012-05-30 | 巴斯利尔药物股份公司 | 环氧丁醇中间体的制备方法 |
PE20070855A1 (es) | 2005-12-02 | 2007-10-14 | Bayer Pharmaceuticals Corp | Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas |
CN101466710B (zh) | 2005-12-02 | 2013-05-29 | 拜尔健康护理有限责任公司 | 用于治疗与血管生成有关的过度增殖性病症和疾病的取代的4-氨基-吡咯并三嗪衍生物 |
WO2007065289A2 (fr) | 2005-12-09 | 2007-06-14 | Basilea Pharmaceutica Ag | 4-oxo-(iso)tretinoine pour le traitement topique des troubles dermatologiques severes |
RU2422454C2 (ru) | 2005-12-09 | 2011-06-27 | Ф. Хоффманн-Ля Рош Аг | Антивирусные нуклеозиды |
WO2007097991A2 (fr) | 2006-02-16 | 2007-08-30 | Pharmasset, Inc. | Méthodes et trousses pour administrer des agents antiviraux |
DE102006015378A1 (de) | 2006-04-03 | 2007-10-04 | Ludwig-Maximilians-Universität München | Verfahren zur Synthese von Organoelementverbindungen |
AR061024A1 (es) | 2006-05-22 | 2008-07-30 | Novartis Ag | Maleato de 5-amino-3- (2'3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d] pirimidin-2-ona. |
US7842672B2 (en) | 2006-07-07 | 2010-11-30 | Gilead Sciences, Inc. | Phosphonate inhibitors of HCV |
WO2008033466A2 (fr) | 2006-09-14 | 2008-03-20 | Combinatorx (Singapore) Pre. Ltd. | Compositions et procédés pour le traitement de maladies virales |
EP2079753A1 (fr) | 2006-11-06 | 2009-07-22 | Boehringer Ingelheim International GmbH | Dérivés de benzyl-benzonitrile substitués par glucopyranosyle, médicaments contenant de tels composés, leur utilisation et procédé pour leur fabrication |
WO2008079206A1 (fr) | 2006-12-20 | 2008-07-03 | Merck & Co., Inc. | Phosphoramidates cycliques nucléosidiques pour le traitement d'infections virales arn dépendantes |
US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
JP2010515680A (ja) | 2007-01-05 | 2010-05-13 | メルク・シャープ・エンド・ドーム・コーポレイション | Rna依存性rnaウイルス感染症の治療用としてのヌクレオシドアリールホスホロアミデート |
US8440813B2 (en) | 2007-01-12 | 2013-05-14 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
EP2125819B1 (fr) | 2007-03-21 | 2014-10-22 | Bristol-Myers Squibb Company | Composés hétérocycliques fusionnés utiles pour le traitement de maladies prolifératives, allergiques, auto-immunes ou inflammatoires |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
WO2008141079A1 (fr) | 2007-05-10 | 2008-11-20 | Biocryst Pharmaceuticals, Inc. | Composés de tétrahydrofuro [3,4-d] dioxolane pour utilisation dans le traitement d'infections virales et de cancer |
CN100532388C (zh) | 2007-07-16 | 2009-08-26 | 郑州大学 | 2’-氟-4’-取代-核苷类似物、其制备方法及应用 |
AU2008286240B2 (en) | 2007-08-03 | 2013-05-23 | Biotron Limited | Hepatitis C antiviral compositions and methods |
KR101502533B1 (ko) | 2007-11-22 | 2015-03-13 | 에스케이케미칼주식회사 | 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법 |
TW200942243A (en) | 2008-03-05 | 2009-10-16 | Biocryst Pharm Inc | Antiviral therapeutic agents |
US8227431B2 (en) | 2008-03-17 | 2012-07-24 | Hetero Drugs Limited | Nucleoside derivatives |
US7863291B2 (en) | 2008-04-23 | 2011-01-04 | Bristol-Myers Squibb Company | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
BRPI0911410A2 (pt) | 2008-04-23 | 2015-10-06 | Gilead Sciences Inc | análogos de carba-nucleosídeo para tratamento antiviral |
WO2010036407A2 (fr) | 2008-05-15 | 2010-04-01 | Biocryst Pharmaceuticals, Inc. | Analogues nucléosidiques antiviraux |
EP2313102A2 (fr) | 2008-07-03 | 2011-04-27 | Biota Scientific Management | Nucléosides bicycliques et nucléotides convenant comme agents thérapeutiques |
PE20160858A1 (es) | 2009-02-10 | 2016-09-03 | Gilead Sciences Inc | Analogos carba-nucleosidicos para tratamiento antiviral |
AR075584A1 (es) | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
EP2408306A4 (fr) | 2009-03-20 | 2012-11-07 | Alios Biopharma Inc | Nucleoside substitue et analogues nucleotidiques |
CA2755950C (fr) | 2009-03-24 | 2017-04-25 | Biocryst Pharmaceuticals, Inc. | Sels pharmaceutiques utiles de 7-[(3r,4r)-3-hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one |
TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
MX2012000959A (es) | 2009-07-21 | 2012-03-06 | Gilead Sciences Inc | Inhibidores de los virus flaviviridae. |
US8455451B2 (en) | 2009-09-21 | 2013-06-04 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
US7973013B2 (en) | 2009-09-21 | 2011-07-05 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
PE20210668A1 (es) | 2009-09-21 | 2021-04-05 | Gilead Sciences Inc | Analogos de carba-nucleosidos sustituidos con 2'-fluoro antivirales |
SI2480559T1 (sl) | 2009-09-21 | 2013-10-30 | Gilead Sciences, Inc. | Postopki in intermediati za pripravo 1'-ciano-karbanukleozidnih analogov |
KR101467858B1 (ko) | 2009-12-28 | 2014-12-02 | 재단법인 생물기술개발중심 | mTOR 및 PI3K 억제제로서의 신규 피리미딘 화합물 |
WO2011123672A1 (fr) | 2010-03-31 | 2011-10-06 | Pharmasset, Inc. | Phosphoramidate de nucléoside de type purine |
EP2752422B1 (fr) | 2010-03-31 | 2017-08-16 | Gilead Pharmasset LLC | Synthèse stéréosélective d'agents actifs contenant du phosphore |
TW201201815A (en) | 2010-05-28 | 2012-01-16 | Gilead Sciences Inc | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
KR20200052384A (ko) * | 2010-07-19 | 2020-05-14 | 길리애드 사이언시즈, 인코포레이티드 | 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법 |
PT2595980E (pt) * | 2010-07-22 | 2014-11-27 | Gilead Sciences Inc | Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae |
TW201305185A (zh) | 2010-09-13 | 2013-02-01 | Gilead Sciences Inc | 用於抗病毒治療之2’-氟取代之碳-核苷類似物 |
BR112013008017A2 (pt) | 2010-09-20 | 2016-06-14 | Gilead Sciences Inc | análogos de carba-nucleosídeo 2-flúor substituídos para tratamento antiviral |
NZ607996A (en) | 2010-09-22 | 2014-07-25 | Alios Biopharma Inc | Substituted nucleotide analogs |
BR112013009029B1 (pt) | 2010-10-15 | 2021-06-29 | Biocryst Pharmaceuticals, Inc. | Métodos e composições para inibição de polimerase |
ES2716158T3 (es) | 2010-11-30 | 2019-06-10 | Gilead Pharmasset Llc | 2'-spiro-nucleótidos para el tratamiento de hepatitis C |
CA2822037A1 (fr) | 2010-12-20 | 2012-06-28 | Gilead Sciences, Inc. | Combinations pour traiter le vhc |
JP2014515023A (ja) | 2011-04-13 | 2014-06-26 | メルク・シャープ・アンド・ドーム・コーポレーション | 2’−置換ヌクレオシド誘導体およびウイルス疾患の処置のためのその使用方法 |
EA201391264A1 (ru) | 2011-04-13 | 2014-03-31 | Джилид Сайэнс, Инк. | 1'-замещенные пиримидиновые n-нуклеозидные аналоги для противовирусного лечения |
ES2639122T3 (es) * | 2011-05-13 | 2017-10-25 | Zoetis Services Llc | Composiciones inmunogénicas de glucoproteína G de virus Hendra y Nipah |
WO2013039861A2 (fr) * | 2011-09-12 | 2013-03-21 | modeRNA Therapeutics | Acides nucléiques modifiés et leurs procédés d'utilisation |
MD4589C1 (ro) | 2011-09-16 | 2019-03-31 | Gilead Pharmasset Llc | Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
US20130143835A1 (en) * | 2011-12-05 | 2013-06-06 | Medivir Ab | HCV Polymerase Inhibitors |
WO2013084165A1 (fr) * | 2011-12-05 | 2013-06-13 | Medivir Ab | Inhibiteurs de vhc polymérase |
EP2794630A4 (fr) * | 2011-12-22 | 2015-04-01 | Alios Biopharma Inc | Analogues de nucléotide phosphorothioate substitués |
NZ702744A (en) | 2012-05-22 | 2016-12-23 | Idenix Pharmaceuticals Llc | D-amino acid compounds for liver disease |
EP2890704B1 (fr) | 2012-08-31 | 2018-02-28 | Novartis AG | Dérivés de 2'-éthynyle nucléoside de traitement d'infections virales |
KR20150054795A (ko) | 2012-09-10 | 2015-05-20 | 에프. 호프만-라 로슈 아게 | B형 간염 바이러스 감염의 치료 및 예방을 위한 6-아미노산 헤테로아릴다이하이드로피리미딘 |
WO2014042433A2 (fr) * | 2012-09-14 | 2014-03-20 | Kainos Medicine, Inc. | Composés et compositions de modulation de l'activité du récepteur adénosine a3 |
CA2890905A1 (fr) | 2012-11-16 | 2014-05-22 | Biocryst Pharmaceuticals, Inc. | Nucleosides antiviraux contenant de l'azasucre |
JP2016501200A (ja) | 2012-11-19 | 2016-01-18 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | ウイルス性疾患を処置するための2−アルキニル置換ヌクレオシド誘導体 |
KR102168621B1 (ko) * | 2012-12-21 | 2020-10-22 | 얀센 바이오파마, 인코퍼레이트. | 치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체 |
US9283242B2 (en) | 2013-01-22 | 2016-03-15 | Massachusetts Institute Of Technology | Uses of dihydro bases |
US10034893B2 (en) | 2013-02-01 | 2018-07-31 | Enanta Pharmaceuticals, Inc. | 5, 6-D2 uridine nucleoside/tide derivatives |
US20140309164A1 (en) | 2013-04-12 | 2014-10-16 | Achillion Pharmaceuticals, Inc. | Deuterated nucleoside prodrugs useful for treating hcv |
US9542154B2 (en) | 2013-06-25 | 2017-01-10 | Intel Corporation | Fused multiply add operations using bit masks |
UA117375C2 (uk) * | 2013-09-04 | 2018-07-25 | Медівір Аб | Інгібітори полімерази hcv |
RS61540B1 (sr) | 2013-09-11 | 2021-04-29 | Inst Nat Sante Rech Med | Postupci i farmaceutske kompozicije za tretiranje infekcije hepatitis b virusa |
UA119050C2 (uk) | 2013-11-11 | 2019-04-25 | Ґілеад Саєнсиз, Інк. | ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ |
EA201691261A1 (ru) | 2014-01-30 | 2016-11-30 | Ф. Хоффманн-Ля Рош Аг | Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b |
PT3114128T (pt) | 2014-03-07 | 2019-02-27 | Hoffmann La Roche | Novas heteroarildihidropirimidinas fundidas em 6 para o tratamento e profilaxia da infeção pelo vírus da hepatite b. |
WO2015173164A1 (fr) | 2014-05-13 | 2015-11-19 | F. Hoffmann-La Roche Ag | Nouvelles dihydroquinolizinones pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b |
US9504701B2 (en) | 2014-06-02 | 2016-11-29 | The Board Of Regents Of The University Of Texas System | Methods for treating viral infections using hydrogen sulfide donors |
US9616076B2 (en) * | 2014-06-02 | 2017-04-11 | The Board Of Regents Of The University Of Texas Systems | Methods for treating viral infections using hydrogen sulfide donors |
WO2016012470A1 (fr) | 2014-07-25 | 2016-01-28 | F. Hoffmann-La Roche Ag | Nouvelles formes amorphes et cristallines de l'acide (3s)-4-[[(4r)-4-(2-chloro-4-fluorophényl)-5-méthoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]méthyl]morpholine-3-carboxilique |
CA2952541C (fr) | 2014-08-14 | 2019-10-01 | F. Hoffmann-La Roche Ag | Pyridazones et triazinones pour le traitement et la prevention de l'infection par le virus de l'hepatite b |
TWI698444B (zh) | 2014-10-29 | 2020-07-11 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
US9637485B2 (en) | 2014-11-03 | 2017-05-02 | Hoffmann-La Roche Inc. | 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection |
WO2016102438A1 (fr) | 2014-12-23 | 2016-06-30 | F. Hoffmann-La Roche Ag | Procédé de préparation d'analogues de 4-phényl-5-alcoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidine |
US9676793B2 (en) | 2014-12-23 | 2017-06-13 | Hoffmann-Laroche Inc. | Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same |
WO2016107832A1 (fr) | 2014-12-30 | 2016-07-07 | F. Hoffmann-La Roche Ag | Nouvelles tétrahydropyridopyrimidines et tétrahydropyridopyridines pour le traitement et la prévention d'une infection par le virus de l'hépatite b |
WO2016107833A1 (fr) | 2014-12-31 | 2016-07-07 | F. Hoffmann-La Roche Ag | Nouveau procédé à haut débit pour la quantification d'adnccc du virus de l'hépatite b (hbv) à partir de lysat cellulaire par pcr en temps réel |
MA41338B1 (fr) | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
EP3250685A1 (fr) | 2015-01-27 | 2017-12-06 | F. Hoffmann-La Roche AG | Adnccc du virus de l'hépatite b (hbv) recombiné, procédé pour générer ce dernier et utilisation associée |
CN107207505B (zh) | 2015-02-11 | 2018-12-14 | 豪夫迈·罗氏有限公司 | 治疗和预防乙型肝炎病毒感染的 2-氧代-6,7-二氢苯并[a]喹嗪-3-甲酸衍生物 |
CA2998189C (fr) | 2015-09-16 | 2021-08-03 | Gilead Sciences, Inc. | Procedes pour le traitement d'infections virales a arenaviridae et coronaviridae |
WO2017184668A1 (fr) | 2016-04-20 | 2017-10-26 | Gilead Sciences, Inc. | Méthodes de traitement d'infections virales à flaviviridae |
BR112019016316A2 (pt) | 2017-02-08 | 2020-03-31 | Biotron Limited | Métodos para o tratamento da influenza |
CN110869028B (zh) | 2017-03-14 | 2023-01-20 | 吉利德科学公司 | 治疗猫冠状病毒感染的方法 |
CN115403626A (zh) | 2017-05-01 | 2022-11-29 | 吉利德科学公司 | 新结晶形式 |
US10675296B2 (en) | 2017-07-11 | 2020-06-09 | Gilead Sciences, Inc. | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
CN111265532A (zh) | 2020-01-21 | 2020-06-12 | 中国人民解放军军事科学院军事医学研究院 | 取代氨基丙酸酯类化合物在治疗2019-nCoV感染中的应用 |
WO2021154687A1 (fr) | 2020-01-27 | 2021-08-05 | Gilead Sciences, Inc. | Procédés de traitement d'infections par sras cov-2 |
-
2015
- 2015-10-27 TW TW104135248A patent/TWI698444B/zh active
- 2015-10-27 TW TW109120726A patent/TWI740546B/zh active
- 2015-10-27 TW TW104135247A patent/TWI687432B/zh active
- 2015-10-27 TW TW109109475A patent/TWI767201B/zh active
- 2015-10-28 BR BR102015027413A patent/BR102015027413A2/pt not_active Application Discontinuation
- 2015-10-29 PE PE2017000745A patent/PE20171439A1/es unknown
- 2015-10-29 JP JP2017520938A patent/JP6220484B1/ja active Active
- 2015-10-29 EA EA201790597A patent/EA032239B1/ru unknown
- 2015-10-29 KR KR1020217039965A patent/KR102453808B1/ko active IP Right Grant
- 2015-10-29 SI SI201530258T patent/SI3212174T1/en unknown
- 2015-10-29 SG SG11201702903TA patent/SG11201702903TA/en unknown
- 2015-10-29 HU HUE15797205A patent/HUE039231T2/hu unknown
- 2015-10-29 CN CN202111041161.1A patent/CN113620992A/zh active Pending
- 2015-10-29 MX MX2017005252A patent/MX2017005252A/es unknown
- 2015-10-29 KR KR1020177014043A patent/KR20170077167A/ko not_active Application Discontinuation
- 2015-10-29 CA CA3184285A patent/CA3184285A1/fr active Pending
- 2015-10-29 EP EP18167340.1A patent/EP3366295B1/fr active Active
- 2015-10-29 CR CR20170483A patent/CR20170483A/es unknown
- 2015-10-29 EP EP15801008.2A patent/EP3212175B1/fr active Active
- 2015-10-29 LT LTEP18167340.1T patent/LT3366295T/lt unknown
- 2015-10-29 CR CR20170165A patent/CR20170165A/es unknown
- 2015-10-29 CN CN202110878274.0A patent/CN113549120A/zh active Pending
- 2015-10-29 PE PE2017002319A patent/PE20180202A1/es unknown
- 2015-10-29 KR KR1020177014110A patent/KR102337664B1/ko active IP Right Grant
- 2015-10-29 CU CUP2017000145A patent/CU20170145A7/xx unknown
- 2015-10-29 HU HUE18167340A patent/HUE049192T2/hu unknown
- 2015-10-29 CN CN201580059611.6A patent/CN107073005B/zh active Active
- 2015-10-29 BR BR112017007636A patent/BR112017007636A2/pt not_active Application Discontinuation
- 2015-10-29 KR KR1020227034888A patent/KR20220140656A/ko active Application Filing
- 2015-10-29 MX MX2017005250A patent/MX2017005250A/es unknown
- 2015-10-29 ES ES15797205.0T patent/ES2674806T3/es active Active
- 2015-10-29 PL PL15797205T patent/PL3212174T3/pl unknown
- 2015-10-29 CA CA2963907A patent/CA2963907C/fr active Active
- 2015-10-29 NZ NZ730809A patent/NZ730809A/en unknown
- 2015-10-29 ME MEP-2018-183A patent/ME03070B/fr unknown
- 2015-10-29 MY MYPI2017701244A patent/MY195823A/en unknown
- 2015-10-29 ES ES18167340T patent/ES2785034T3/es active Active
- 2015-10-29 DK DK18167340.1T patent/DK3366295T3/da active
- 2015-10-29 DK DK15797205.0T patent/DK3212174T3/en active
- 2015-10-29 WO PCT/US2015/057933 patent/WO2016069826A1/fr active Application Filing
- 2015-10-29 AR ARP150103506A patent/AR102468A1/es unknown
- 2015-10-29 UY UY0001036376A patent/UY36376A/es unknown
- 2015-10-29 CN CN201580059613.5A patent/CN107074902A/zh active Pending
- 2015-10-29 SG SG11201702904RA patent/SG11201702904RA/en unknown
- 2015-10-29 SI SI201531764T patent/SI3212175T1/sl unknown
- 2015-10-29 MA MA040872A patent/MA40872A/fr unknown
- 2015-10-29 EA EA201790630A patent/EA201790630A1/ru unknown
- 2015-10-29 UA UAA201703584A patent/UA121485C2/uk unknown
- 2015-10-29 NZ NZ745328A patent/NZ745328A/en unknown
- 2015-10-29 WO PCT/US2015/057932 patent/WO2016069825A1/fr active Application Filing
- 2015-10-29 MA MA040867A patent/MA40867A/fr unknown
- 2015-10-29 CA CA2963832A patent/CA2963832C/fr active Active
- 2015-10-29 KR KR1020177014042A patent/KR101822348B1/ko active IP Right Grant
- 2015-10-29 PL PL15801008T patent/PL3212175T3/pl unknown
- 2015-10-29 AU AU2015339222A patent/AU2015339222B2/en active Active
- 2015-10-29 RS RS20180822A patent/RS57425B1/sr unknown
- 2015-10-29 WO PCT/US2015/057934 patent/WO2016069827A1/fr active Application Filing
- 2015-10-29 PT PT181673401T patent/PT3366295T/pt unknown
- 2015-10-29 EP EP15797205.0A patent/EP3212174B1/fr active Active
- 2015-10-29 CN CN202111480947.3A patent/CN114191438A/zh active Pending
- 2015-10-29 NZ NZ730803A patent/NZ730803A/en unknown
- 2015-10-29 JP JP2017520934A patent/JP6487547B2/ja active Active
- 2015-10-29 US US14/926,062 patent/US9724360B2/en active Active
- 2015-10-29 AR ARP150103505A patent/AR102467A1/es unknown
- 2015-10-29 ES ES15801008T patent/ES2904298T3/es active Active
- 2015-10-29 MD MDA20170046A patent/MD20170046A2/ro not_active Application Discontinuation
- 2015-10-29 TR TR2018/09518T patent/TR201809518T4/tr unknown
- 2015-10-29 PT PT157972050T patent/PT3212174T/pt unknown
- 2015-10-29 LT LTEP15797205.0T patent/LT3212174T/lt unknown
- 2015-10-29 EP EP20152978.1A patent/EP3695844A1/fr active Pending
- 2015-10-29 SG SG10202008772UA patent/SG10202008772UA/en unknown
- 2015-10-29 SI SI201531150T patent/SI3366295T1/sl unknown
- 2015-10-29 EP EP21209687.9A patent/EP4036099A1/fr active Pending
- 2015-10-29 PT PT158010082T patent/PT3212175T/pt unknown
- 2015-10-29 US US14/926,063 patent/US11344565B2/en active Active
- 2015-10-29 PL PL18167340T patent/PL3366295T3/pl unknown
- 2015-10-29 MA MA052506A patent/MA52506A/fr unknown
- 2015-10-29 AU AU2015339223A patent/AU2015339223B2/en active Active
- 2015-10-29 CU CUP2017000056A patent/CU20170056A7/es unknown
-
2016
- 2016-08-24 US US15/246,240 patent/US9949994B2/en active Active
-
2017
- 2017-04-04 IL IL251560A patent/IL251560A0/en unknown
- 2017-04-06 PH PH12017500631A patent/PH12017500631A1/en unknown
- 2017-04-12 IL IL251707A patent/IL251707B/en active IP Right Grant
- 2017-04-21 MX MX2020012560A patent/MX2020012560A/es unknown
- 2017-04-24 DO DO2017000103A patent/DOP2017000103A/es unknown
- 2017-04-24 SV SV2017005424A patent/SV2017005424A/es unknown
- 2017-04-24 EC ECIEPI201725261A patent/ECSP17025261A/es unknown
- 2017-04-24 CO CONC2017/0003960A patent/CO2017003960A2/es unknown
- 2017-04-26 CL CL2017001040A patent/CL2017001040A1/es unknown
- 2017-04-27 SA SA517381419A patent/SA517381419B1/ar unknown
- 2017-06-06 JP JP2017111470A patent/JP6757294B2/ja active Active
- 2017-10-24 CL CL2017002693A patent/CL2017002693A1/es unknown
- 2017-10-30 EC ECIEPI201772474A patent/ECSP17072474A/es unknown
- 2017-11-01 UY UY0001037464A patent/UY37464A/es not_active Application Discontinuation
- 2017-11-03 SV SV2017005561A patent/SV2017005561A/es unknown
-
2018
- 2018-01-19 ZA ZA201800414A patent/ZA201800414B/en unknown
- 2018-02-22 US US15/902,690 patent/US10251898B2/en active Active
- 2018-07-06 JP JP2018129006A patent/JP6671424B2/ja active Active
- 2018-07-17 HR HRP20181130TT patent/HRP20181130T1/hr unknown
- 2018-08-10 CY CY20181100844T patent/CY1120893T1/el unknown
- 2018-10-23 AU AU2018253483A patent/AU2018253483B2/en active Active
-
2019
- 2019-01-07 JP JP2019000664A patent/JP2019048901A/ja not_active Withdrawn
- 2019-01-23 HK HK19101159.4A patent/HK1258795A1/zh unknown
- 2019-02-12 US US16/274,049 patent/US10695357B2/en active Active
- 2019-02-22 AU AU2019201232A patent/AU2019201232B2/en active Active
- 2019-11-22 US US16/692,966 patent/US20200197422A1/en not_active Abandoned
-
2020
- 2020-02-14 JP JP2020023613A patent/JP2020090536A/ja not_active Withdrawn
- 2020-03-06 JP JP2020038878A patent/JP7158428B2/ja active Active
- 2020-04-14 CY CY20201100351T patent/CY1122946T1/el unknown
- 2020-05-22 US US16/881,419 patent/US11266666B2/en active Active
- 2020-06-12 AU AU2020203892A patent/AU2020203892A1/en not_active Abandoned
- 2020-07-08 PH PH12020551055A patent/PH12020551055A1/en unknown
-
2021
- 2021-03-09 AU AU2021201474A patent/AU2021201474B2/en active Active
-
2022
- 2022-02-07 US US17/665,724 patent/US20220354873A1/en active Pending
- 2022-02-10 JP JP2022019651A patent/JP2022065066A/ja not_active Withdrawn
- 2022-02-18 JP JP2022024119A patent/JP2022068297A/ja active Pending
- 2022-12-09 AU AU2022283772A patent/AU2022283772A1/en not_active Abandoned
-
2023
- 2023-05-02 AU AU2023202679A patent/AU2023202679A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA40867A (fr) | Méthodes pour le traitement d'infections virales à filoviridae | |
MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
MA45192A (fr) | Traitement d'association | |
MA43135A (fr) | Compositions et méthodes pour le du traitement du cancer | |
DK3349758T3 (da) | Fremgangsmåder til behandling af arenaviridae-virusinfektioner | |
DK3347030T3 (da) | Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme | |
MA44083A (fr) | Composés de biarylmonobactame pour le traitement d'infections bactériennes | |
MA41028A (fr) | Méthodes et formulations pour le traitement de pathologies oculaires vasculaires | |
MA55694A (fr) | Méthodes de conditionnement de patients pour la thérapie cellulaire t | |
MA41449A (fr) | Polythérapies pour le traitement de cancers | |
WO2015153889A3 (fr) | Substances et procédés pour le traitement d'une infection virale latente | |
MA39748A (fr) | Cenicriviroc pour le traitement de la fibrose | |
MA41119A (fr) | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique | |
DK3466432T3 (da) | Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner | |
MA47719A (fr) | Esketamine pour le traitement de la dépression | |
DK3099298T3 (da) | Kombinationsterapier med zidovudin til behandling af mikrobielle infektioner | |
SG11201609652RA (en) | Treatment of polybacterials infections | |
HK1231402A1 (zh) | 治療 型肝炎和 型肝炎病毒感染的方法 | |
MA42999A (fr) | Polythérapie pour le traitement de malignités | |
DK3436074T3 (da) | Thiazolidforbindelser til behandling af virale infektioner | |
IL256327B (en) | Pharmaceutical preparations for the treatment of viral problems of the eye | |
MA43230A (fr) | Méthodes et compositions pour le traitement d'une épidermolyse bulleuse | |
MA43570A (fr) | Thérapie génique pour traiter l'hypercholestérolémie familiale | |
MA43106A (fr) | Traitement de l'oligo-ovulation associée à la stéatose hepatique | |
MA45973A (fr) | Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple |